Cachexia

Annals of Internal Medicine

Volumn 133, Issue 8, 2000, Pages 622-634

  Kotler, D P ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; APPETITE STIMULANT; CARNITINE; CYTOKINE; DRONABINOL; ERYTHROPOIETIN; HUMAN GROWTH HORMONE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MELATONIN; OMEGA 3 FATTY ACID; PENTOXIFYLLINE; PROTEIN; TESTOSTERONE; TETRAHYDROCANNABINOLIC ACID; THALIDOMIDE;

AGING; CACHEXIA; CALORIC INTAKE; DISEASE ASSOCIATION; ENERGY; FEEDING; HUMAN; INFECTION; LEAN BODY WEIGHT; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; REVIEW; SKELETAL MUSCLE; STARVATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TISSUE INJURY;

EID: 0033775544     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-133-8-200010170-00015     Document Type: Review

References (121)

1. The immediate causes of death in cancer
2. Wasting as independent risk factor for mortality in chronic heart failure
3. The magnitude of bodycell-mass depletion and the timing of death from wasting in AIDS
4. Starvation in man
5. Sarcopenia: Origins and clinical relevance
6. Time dependent variation in weight and body composition in healthy adults
7. Changes in body composition in patients with small-cell cancer. The effect of total parenteral nutrition as an adjunct to chemotherapy
8. Body composition studies in patients with the acquired immunodeficiency syndrome
9. Daily energy expenditure in free-living heart failure patients
10. Mechanisms causing loss of lean body mass in kidney disease
11. Rheumatoid cachexia: Cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation
12. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway
13. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins
14. Relative influences of sex, race, environment, and HIV infection upon body composition in adults
15. Lean body mass-body fat interrelationships in humans
16. Regulation of the acute phase response by cytokines
17. C-reactive protein. A historical overview
18. Multiple cytokines stimulate hepatic lipid synthesis in vivo
19. Human very low density lipoproteins and chylomicrons can protect against endotoxin-induced death in mice
20. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death
21. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
22. Energy expenditure and wasting in human immunodeficiency vires infection
23. Mechanisms of decreased food intake during weight loss in adult Crohn's disease patients without obvious malabsorption
24. Total daily energy expenditure relative to resting energy expenditure in clinically stable patients with COPD
25. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin
26. Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1)
27. Hypothesis: Leukocyte endogenous mediator/endogenous pyrogen/lymphocyte-activating factor modulates the development of nonspecific and specific immunity and affects nutritional status
28. Parabiotic transfer of cancer anorexia/cachexia in male rats
29. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle in duces chromic cachexia, while implantation in brain induces predominantly acute anorexia
30. Changes in energy expenditure resulting from altered body weight
31. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters
32. Endotoxin-induced alteration in the expression of leptin and β3-adrenergic receptor in adipose tissue
33. Multiple cytokines and acute inflammation raise mouse leptin levels: Potential role in inflammatory anorexia
34. Serum leptin levels in the acquired immunodeficiency syndrome
35. Plasma concentration of total leptin and human lung-cancer-associated cachexia
36. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients
37. Circulating leptin in patients with chronic obstructive pulmonary disease
38. Plasma leptin is related to proinflammatory status and dietary intake in patients with chronic obstructive pulmonary disease
39. Leptin produces anorexia and weight loss without inducing an acute phase response or protein wasting
40. Elevated serum interleukin-6 levels in patients with pancreatic cancer
41. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer
42. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer
43. Cytokine levels (IL-6 and IFN-γ), acute phase response and nutritional status as prognostic factors in lung cancer
44. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer
45. Relationship between serum levels of interleukin 6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma
46. Serum levels of interleukin-10 and interleukin-12 in patients with colorectal cancer
47. Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response
48. Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response
49. Acute-phase protein response and survival duration of patients with pancreatic cancer
50. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor
51. Mechanism of muscle protein degradation induced by a cancer cachectic factor
52. Pathophysiology and treatment of the AIDS wasting syndrome
53. Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting
54. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting
55. Plasma cytokines, cytokine antagonists, and disease progression in African women infected with HIV-1
56. Whole-body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection
57. Increased plasma gln and Leu Ra and inappropriately low muscle protein synthesis rate in AIDS wasting
58. Adjuvant arthritis as a model of inflammatory cachexia
59. Insights into the pathogenesis of chronic heart failure: Immune activation and cachexia
60. Increased resting metabolic rate in patients with congestive heart failure
61. Tumour necrosis factor a as a predictor of impaired peak leg blood flow in patients with chronic heart failure
62. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure
63. Increased oxidative stress in patients with congestive heart failure
64. Loss of bone mineral in patients with cachexia due to chronic heart failure
65. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis
66. Mechanisms of hypoalbuminemia in hemodialysis patients
67. Tumor necrosis factor-α levels and weight loss in chronic obstructive pulmonary disease
68. 2 cost of ventilation contributes to tissue wasting in chronic obstructive pulmonary disease
69. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors
70. Monocyte cytokine production in an elderly population: Effect of age and inflammation
71. Inflammatory mediators in children with protein-energy malnutrition
72. Sequential changes in the metabolic response in severely septic patients during the first 23 days after the onset of peritonitis
73. Effect of home total parenteral nutrition upon body composition in patients with acquired immunodeficiency syndrome
74. A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma: Influence on survival
75. Megestrol acetate in neoplastic anorexia/cachexia: Clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy
76. Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: A randomized, placebo-controlled trial
77. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative
78. Recombinant human growth hormone in patients with HIV-associated wasting. A randomized, placebo-controlled trial. Serostim Study Group
79. Short-term growth hormone administration at the time of opportunistic infections in HIV-positive patients
80. Growth hormone replacement in healthy older men improves body composition but not functional ability
81. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study
82. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy
83. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy
84. A placebo-controlled study of growth hormone in patients with congestive heart failure
85. Effect of growth hormone and protein intake on tumor growth and host cachexia
86. Increased mortality associated with growth hormone treatment in critically ill adults
87. Oxandrolone, an anabolic steroid, significantly increases the rate of weight gain in the recovery phase after major burns
88. Safety and efficacy of nandrolone decanoate for treatment of wasting m patients with HIV infection
89. Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial
90. Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels
91. Sustained anabolic effects of long-term androgen administration in men with AIDS wasting
92. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study
93. Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss
94. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients
95. Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial
96. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients
97. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: Results of a Department of Veterans Affairs cooperative study
98. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: Effects on functional capacity, quality of life, and clinical outcome
99. Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus
100. Does growth hormone therapy in conjunction with resistance exercise increase muscle force production and muscle mass in men and women aged 60 years or older?
101. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial
102. Δ9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cell
103. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection
104. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled trial
105. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants
106. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors
107. A pilot study of megestrol acetate and ibuprofen in the treatment of cachexia m gastrointestinal cancer patients
108. Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study
109. The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer
110. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model
111. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice
112. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways
113. Anti-TNF treatment reverts increased muscle ubiquitin gene expression in tumour-bearing rats
114. Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor
115. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-α on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells
116. Muscle protein waste in tumor-bearing rats is effectively antagonized by a β2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway
117. Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate
118. Suppression of carcass weight loss in cachexia in rats bearing Leydig cell tumor by the novel compound NO-1886, a lipoprotein lipase activator
119. Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock
120. Serotonergic blockade in the treatment of the cancer anorexia-cachexia syndrome